Chidamide, a novel histone deacetylase inhibitor, inhibits laryngeal cancer progression in vitro and in vivo
The International Journal of Biochemistry & Cell Biology · 2023
DOI: 10.1016/j.biocel.2023.106398 ↗Kurz gefasst
Fachartikel in der Zeitschrift The International Journal of Biochemistry & Cell Biology, 2023. Verfasst von Xinyu Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Hauptthemen laut MEDLINE: Laryngeal Neoplasms, Carcinoma. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Heilongjiang Province.
Abstract (Originalsprache)
Although surgery is an important treatment for laryngeal cancer, surgery has a significant negative impact on the quality of life of patients, and many patients have poor tolerance to surgery. Therefore, alternative chemotherapeutic drugs are an important research hotspot. Chidamide is a histone deacetylase inhibitor that selectively inhibits the expression of type I and IIb histone deacetylases (1, 2, 3 and 10). It has a significant anticancer effect on a variety of solid tumours. This study verified the inhibitory effect of chidamide on laryngeal carcinoma. We conducted a variety of cellular and animal experiments to explore how chidamide inhibits the development of laryngeal cancer. The results showed that chidamide had significant antitumour activity against laryngeal carcinoma cells and xenografts and could induce cell apoptosis, ferroptosis and pyroptosis. This study provides a potential option for the treatment of laryngeal cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China.
- Department of Otorhinolaryngology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
- Department of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Electronic address: tianlinli78@163.com.
- Department of Otorhinolaryngology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. Electronic address: liuming_harbin@126.com.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Heilongjiang Province
Zitieren
APA
Liu, X., Li, W., Xu, L., Chen, X., Zhao, R., Guo, Y., Ge, J., Yang, Z., Li, L., Zhang, J., Cao, J., Shao, Y., Guo, X., Tian, L., & Liu, M. (2023). Chidamide, a novel histone deacetylase inhibitor, inhibits laryngeal cancer progression in vitro and in vivo. The International Journal of Biochemistry & Cell Biology. https://doi.org/10.1016/j.biocel.2023.106398
Vancouver
Liu X, Li W, Xu L, Chen X, Zhao R, Guo Y, et al. Chidamide, a novel histone deacetylase inhibitor, inhibits laryngeal cancer progression in vitro and in vivo. The International Journal of Biochemistry & Cell Biology. 2023. doi:10.1016/j.biocel.2023.106398
BibTeX
@article{Liu2023,
author = {Liu, Xinyu and Li, Wenjing and Xu, Licheng and Chen, Xiaoxue and Zhao, Rui and Guo, Yan and Ge, Jingchun and Yang, Zhenming and Li, Liang and Zhang, Jiarui and Cao, Jing and Shao, Yue and Guo, Xinyue and Tian, Linli and Liu, Ming},
title = {Chidamide, a novel histone deacetylase inhibitor, inhibits laryngeal cancer progression in vitro and in vivo},
journal = {The International Journal of Biochemistry & Cell Biology},
year = {2023},
doi = {10.1016/j.biocel.2023.106398}
}
EUVIMED